Skip to main content

Devonian Health Group Inc.

corporate_fare Company Profile

Devonian Health Group Inc.

DVHGF·OTC·Life Sciences·CIK 0002000684

Devonian Health Group Inc. develops botanical drugs. The company's primary product candidate is Thykamine, which is undergoing several clinical trials: a phase 3 clinical trial for treating Atopic dermatitis in adults, a phase 2/3 clinical trial for Atopic dermatitis in children, a phase 2 clinical trial for Hand-Foot Syndrome (HFS) associated with chemotherapy, a phase 2/3 clinical trial for Radiodermatitis associated with radiotherapy, and a phase 2a clinical trial for ulcerative colitis. Devonian Health Group Inc. also develops Pantoprazole Magnesium for gastric reflux treatment and Cleo-35 for hormonal acne in women. Additionally, the company offers R-Spinasome anti-aging cream, serum, and regenerating creams, as well as anti-aging products under the Purgenesis brand, which include day, night, and eye creams. Devonian Health Group Inc. is based in Québec, Canada.

Devonian Health Group Inc. (OTC:DVHGF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for DVHGF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-03-25, rated 8/10.

Recent high-impact activity:

  • Devonian Health Reports Sharply Increased Losses, Low Cash; 60-to-1 Reverse Split Effected

Short Interest & Short Volume

4.90 days to cover

FINRA reported short interest of 4,315 shares in DVHGF as of the September 15, 2026 settlement, a 28666.7% increase from the prior period — about 4.9 days to cover at its recent average daily volume.

Short interest (bi-monthly positions)4,315 shares as of September 15, 2026
Change vs prior period▲ 28666.7%
Days to cover4.90 at avg daily volume of 880

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$5.88 +0.11% today
52-week range · as of 2026-03-25 $0.60 – $39.59
Market cap
$16.34M
Volume
100 (0.5× avg)
3-mo avg 190.7
Last traded · 2026-09-29

show_chartPrice Chart

Loading chart...

feed DVHGF - Latest Insights

DVHGF
Mar 25, 2026, 4:23 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Devonian Health Reports Sharply Increased Losses, Low Cash; 60-to-1 Reverse Split Effected
Price at Filing: $10.65
Real-time Price: $5.88 info
Change: -$4.78 (-45%) info
Market Cap: $16.338M info
Sentiment: Negative
View Wiseek Article
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets